HRG-β3 inhibitors are a class of compounds designed to specifically target and inhibit the activity of HRG-β3, a member of the heregulin family of proteins. HRG-β3 (heregulin-β3) is one of several isoforms of the heregulin protein family that plays a crucial role in various cellular signaling pathways. These inhibitors work by binding to HRG-β3 and preventing its interaction with receptors such as ErbB3 and ErbB4, which are part of the ErbB receptor family. By interfering with HRG-β3's ability to engage with its target receptors, the inhibitors modulate the downstream signaling cascades that are typically triggered by HRG-β3's activity, affecting cellular processes such as growth, differentiation, and intracellular communication.
HRG-β3 inhibitors can vary widely depending on their chemical makeup, but they generally possess moieties that enable selective binding to HRG-β3. These compounds are often designed with high specificity for HRG-β3 to minimize off-target effects on other proteins. The design of HRG-β3 inhibitors is guided by structural biology, which allows for precise interactions at the molecular level, ensuring that the binding affinity is strong enough to effectively block HRG-β3 function. HRG-β3 inhibitors may be synthesized using organic chemistry techniques or discovered through high-throughput screening of chemical libraries. Their development involves fine-tuning molecular features such as hydrophobicity, charge distribution, and molecular size to optimize their performance in biochemical environments.
产品名称 | CAS # | 产品编号 | 数量 | 价格 | 应用 | 排名 |
---|---|---|---|---|---|---|
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | ¥801.00 ¥1038.00 | 8 | |
血管紧张素 II 受体拮抗剂可能会影响血管功能和相关信号通路。 | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | ¥1433.00 | 18 | |
另一种血管紧张素 II 受体拮抗剂,可能影响血压和血管生成。 | ||||||
Atorvastatin | 134523-00-5 | sc-337542A sc-337542 | 50 mg 100 mg | ¥2843.00 ¥5585.00 | 9 | |
抑制 HMG-CoA 还原酶,可能会影响胆固醇水平以及与炎症和血管生成有关的细胞信号传导。 | ||||||
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | ¥2031.00 ¥3554.00 | 2 | |
抑制多种参与血管生成的酪氨酸激酶,可能会影响 HRG-β3 可能参与的过程。 | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | ¥1230.00 ¥3949.00 | 8 | |
调节免疫反应和抑制血管生成,可能对 HRG-β3 相关途径产生影响。 | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | ¥632.00 ¥2933.00 ¥4693.00 | 129 | |
抑制 RAF 激酶和其他受体,可影响细胞增殖和血管生成。 | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | ¥869.00 | 2 | |
激活 AMPK,可能影响与 HRG-β3 相关的代谢途径和细胞生长。 | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | ¥1726.00 | 5 | |
抑制布鲁顿酪氨酸激酶,可能影响 B 细胞信号传导和免疫反应。 |